Prima BioMed (IMMP) Competitors $1.72 -0.02 (-1.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.72 0.00 (-0.29%) As of 08/1/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. SYRE, VERV, AMPH, RCUS, LENZ, ORIC, AVXL, REPL, MLYS, and PROKShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Spyre Therapeutics (SYRE), Verve Therapeutics (VERV), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Oric Pharmaceuticals (ORIC), Anavex Life Sciences (AVXL), Replimune Group (REPL), Mineralys Therapeutics (MLYS), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Spyre Therapeutics Verve Therapeutics Amphastar Pharmaceuticals Arcus Biosciences LENZ Therapeutics Oric Pharmaceuticals Anavex Life Sciences Replimune Group Mineralys Therapeutics ProKidney Spyre Therapeutics (NASDAQ:SYRE) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Which has higher valuation and earnings, SYRE or IMMP? Prima BioMed has higher revenue and earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,101.30-$208.02M-$3.77-4.31Prima BioMed$5.14M48.87-$28.01MN/AN/A Do analysts recommend SYRE or IMMP? Spyre Therapeutics presently has a consensus price target of $53.40, suggesting a potential upside of 228.41%. Prima BioMed has a consensus price target of $7.00, suggesting a potential upside of 306.98%. Given Prima BioMed's higher probable upside, analysts plainly believe Prima BioMed is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of SYRE or IMMP? 80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, SYRE or IMMP? Spyre Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Does the media prefer SYRE or IMMP? In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 3 articles in the media. Spyre Therapeutics' average media sentiment score of 1.10 beat Prima BioMed's score of 0.25 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SYRE or IMMP more profitable? Prima BioMed's return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -77.46% -41.06% Prima BioMed N/A N/A N/A SummarySpyre Therapeutics beats Prima BioMed on 8 of the 13 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$254.11M$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E RatioN/A17.6228.6723.80Price / Sales48.87178.97373.5466.64Price / CashN/A41.9535.4557.96Price / Book1.648.508.275.55Net Income-$28.01M-$55.06M$3.24B$259.03M7 Day PerformanceN/A-3.98%-3.69%-4.59%1 Month Performance1.18%9.59%4.33%4.46%1 Year Performance-14.00%6.72%25.95%18.03% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.4453 of 5 stars$1.72-1.1%$7.00+307.0%-17.1%$254.11M$5.14M0.002,021News CoverageSYRESpyre Therapeutics2.3063 of 5 stars$16.35+0.4%$53.40+226.6%-39.6%$981.89M$890K0.0073News CoveragePositive NewsUpcoming EarningsGap DownVERVVerve Therapeutics3.3594 of 5 stars$10.93+0.2%$14.57+33.3%N/A$972.55M$32.33M-5.18110News CoverageAMPHAmphastar Pharmaceuticals4.3834 of 5 stars$21.19+2.8%$32.33+52.6%-50.0%$972.01M$731.97M7.682,028News CoverageUpcoming EarningsRCUSArcus Biosciences2.1528 of 5 stars$9.27+1.3%$21.29+129.7%-41.8%$968.85M$258M-2.21500Upcoming EarningsLENZLENZ Therapeutics1.5155 of 5 stars$33.58-0.4%$46.60+38.8%+21.7%$949.37MN/A0.00110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionORICOric Pharmaceuticals4.5629 of 5 stars$11.06+0.5%$18.57+67.9%-4.6%$938.32MN/A-5.9180News CoveragePositive NewsAVXLAnavex Life Sciences3.6596 of 5 stars$11.16+1.6%$44.00+294.3%+70.2%$937.88MN/A-20.2940News CoverageUpcoming EarningsREPLReplimune Group3.8863 of 5 stars$12.32+1.9%$21.00+70.5%-25.6%$931.98MN/A-4.01210Trending NewsAnalyst UpgradeOptions VolumeGap DownHigh Trading VolumeMLYSMineralys Therapeutics2.558 of 5 stars$13.62-4.3%$32.25+136.8%+13.4%$927.44MN/A-3.6528News CoverageInsider TradePROKProKidney3.2738 of 5 stars$3.22+2.2%$6.25+94.1%+29.4%$922M$80K-5.373Upcoming EarningsGap Down Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Verve Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Arcus Biosciences Alternatives LENZ Therapeutics Alternatives Oric Pharmaceuticals Alternatives Anavex Life Sciences Alternatives Replimune Group Alternatives Mineralys Therapeutics Alternatives ProKidney Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
